694479-85-1

Basic information

• Product Name: 3-Pyridinecarboxamide, 1,2-dihydro-5-iodo-6-methyl-N-[[4-(methylsulfonyl)phenyl]methyl]-2-oxo- 1-[3-(trifluoromethyl)phenyl]-
• CAS NO: 694479-85-1
• Molecular Formula: C22H18F3IN2O4S
• Molecular Weight: 590.362
• Mol File: 694479-85-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-Pyridinecarboxamide, 1,2-dihydro-5-iodo-6-methyl-N-[[4-(methylsulfonyl)phenyl]methyl]-2-oxo- 1-[3-(trifluoromethyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarboxamide, 1,2-dihydro-5-iodo-6-methyl-N-[[4-(methylsulfonyl)phenyl]methyl]-2-oxo- 1-[3-(trifluoromethyl)phenyl]-(694479-85-1)
• EPA Substance Registry System: 3-Pyridinecarboxamide, 1,2-dihydro-5-iodo-6-methyl-N-[[4-(methylsulfonyl)phenyl]methyl]-2-oxo- 1-[3-(trifluoromethyl)phenyl]-(694479-85-1)

Safety Data

• Hazardous Substances Data: 694479-85-1(Hazardous Substances Data)

Upstream product

• 694475-15-5 6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 

Downstream Products

• 848140-02-3 C₂₉H₃₀F₃N₃O₄SSi 
• 848140-64-7 5-cyano-6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 

Relevant articles and documents

2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL.

The invention provides compounds of formula (1) wherein R1, R3, R4, R5, R6, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharma

2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE

There are provided novel compounds of formula (I), wherein R1, R2, R4, R5, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes

2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE

There are provided novel compounds of formula (I) wherein R?1?, R?4?, R?5?, G?1?, G?2?, X, L, Y?1?, Y?2? and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.